Posted by Franco Cavaleri at February 5, 2019 5:45 am Uncategorized

Franco Cavaleri, Ph.D candidate Biologic Pharmamedical Research Surrey, BC CANADA

IN PEER-REVIEW AWAITING PUBLICATION

ABSTRACT

 

The curcumin extract, although relatively isolated from the rest of the plant’s constituents, still exhibits an expansive polypharmacology. The extract is made up of three main curcuminoid analogues: diferuloylmethane (Curcumin I), desmethoxycurcumin (Curcumin II) and bis-desmethoxycurcumin (Curcumin III) [1]. Each curcuminoid analogue displays homologous structure with slight differences that should contribute to differential pharmacology. The study of these curcuminoids in isolation using different subcellular targets and cell lines may help us better understand the mechanisms involved in the curcumin extract’s total polypharmacology. This research can also help us determine how the pharmacology of these curcuminoid analogues might be used with greater drug target selectivity. As a start to this lengthy process the HEK293T cell line is chosen for transfection with a basic NF-kB reporter plasmid to study, by Luciferase Assay, the inhibitive potential of the curcuminoids in isolation. All three curcuminoids are shown here to inhibit p65-p50 (one of the NF-kB family proteins) activation in TNFα stimulated HEK293T cells with a comparable level of inhibitive activity. Each of the three curcuminoids exhibits the same IC50 in two different curcuminoid contexts studied with regards to NF-kB inhibition. We will continue to study these curcuminoid analogues with a cautious expectation that they will exhibit differential pharmacology with respect to alternative targets we will study.

 

FULL ARTICLE COMING SOON

Leave a Comment